用于过继免疫治疗的人工抗原呈递细胞。
Artificial antigen-presenting cells for use in adoptive immunotherapy.
机构信息
Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.
出版信息
Cancer J. 2010 Jul-Aug;16(4):374-81. doi: 10.1097/PPO.0b013e3181eb33a6.
Abstract
The observation that T cells can recognize and specifically eliminate cancer cells has spurred interest in the development of efficient methods to generate large numbers of T cells with specificity for tumor antigens that can be harnessed for use in cancer therapy. Recent studies have demonstrated that during encounter with tumor antigen, the signals delivered to T cells by professional antigen-presenting cells can affect T-cell programming and their subsequent therapeutic efficacy. This has stimulated efforts to develop artificial antigen-presenting cells that allow optimal control over the signals provided to T cells. In this review, we will discuss the advantages and disadvantages of cellular and acellular artificial antigen-presenting cell systems and their use in T-cell adoptive immunotherapy for cancer.
摘要
观察到 T 细胞可以识别和特异性消除癌细胞，这激发了人们开发有效方法的兴趣，以生成大量具有针对肿瘤抗原特异性的 T 细胞，这些 T 细胞可用于癌症治疗。最近的研究表明，在与肿瘤抗原接触时，专业抗原呈递细胞向 T 细胞传递的信号可以影响 T 细胞的编程及其随后的治疗效果。这激发了人们开发人工抗原呈递细胞的努力，以便对提供给 T 细胞的信号进行最佳控制。在这篇综述中，我们将讨论细胞和非细胞人工抗原呈递细胞系统的优缺点及其在癌症的 T 细胞过继免疫治疗中的应用。
相似文献
1
Artificial antigen-presenting cells for use in adoptive immunotherapy.
Cancer J. 2010 Jul-Aug;16(4):374-81. doi: 10.1097/PPO.0b013e3181eb33a6.
2
Artificial Antigen Presenting Cells: An Off the Shelf Approach for Generation of Desirable T-Cell Populations for Broad Application of Adoptive Immunotherapy.
Adv Genet Eng. 2015;4(3). Epub 2015 Oct 5.
3
Artificial Antigen-Presenting Cells for Immunotherapies.
Methods Mol Biol. 2017;1530:343-353. doi: 10.1007/978-1-4939-6646-2_21.
4
Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells.
Trends Biotechnol. 2014 Sep;32(9):456-65. doi: 10.1016/j.tibtech.2014.06.007. Epub 2014 Jul 3.
5
Connecting the dots: artificial antigen presenting cell-mediated modulation of natural killer T cells.
J Interferon Cytokine Res. 2012 Nov;32(11):505-16. doi: 10.1089/jir.2012.0045. Epub 2012 Oct 10.
6
Human cell-based artificial antigen-presenting cells for cancer immunotherapy.
Immunol Rev. 2014 Jan;257(1):191-209. doi: 10.1111/imr.12129.
7
Nanoscale artificial antigen presenting cells for cancer immunotherapy.
Mol Immunol. 2018 Jun;98:13-18. doi: 10.1016/j.molimm.2018.02.016. Epub 2018 Mar 7.
8
Biodegradable Cationic Polymer Blends for Fabrication of Enhanced Artificial Antigen Presenting Cells to Treat Melanoma.
ACS Appl Mater Interfaces. 2021 Feb 24;13(7):7913-7923. doi: 10.1021/acsami.0c19955. Epub 2021 Feb 12.
9
Potential advantages of CD1-restricted T cell immunotherapy in cancer.
Mol Immunol. 2018 Nov;103:200-208. doi: 10.1016/j.molimm.2018.09.025. Epub 2018 Oct 8.
10
HLA-Class II Artificial Antigen Presenting Cells in CD4 T Cell-Based Immunotherapy.
Front Immunol. 2019 May 17;10:1081. doi: 10.3389/fimmu.2019.01081. eCollection 2019.
引用本文的文献
1
Diatom-Based Artificial Antigen-Presenting Cells: A Novel Approach for Adaptive Immune Modulation.
ACS Appl Mater Interfaces. 2025 Jul 2;17(26):37718-37734. doi: 10.1021/acsami.5c07766. Epub 2025 Jun 18.
2
Oncolytic virus encoding 4-1BBL and IL15 enhances the efficacy of tumor-infiltrating lymphocyte adoptive therapy in HCC.
Cancer Gene Ther. 2025 Jan;32(1):71-82. doi: 10.1038/s41417-024-00853-w. Epub 2024 Nov 20.
3
Engineering potent chimeric antigen receptor T cells by programming signaling during T-cell activation.
Sci Rep. 2024 Sep 12;14(1):21331. doi: 10.1038/s41598-024-72392-1.
4
Adoptive neoantigen-reactive T cell therapy: improvement strategies and current clinical researches.
Biomark Res. 2023 Apr 17;11(1):41. doi: 10.1186/s40364-023-00478-5.
5
Enhancing CAR-T cell functionality in a patient-specific manner.
Nat Commun. 2023 Jan 31;14(1):506. doi: 10.1038/s41467-023-36126-7.
6
Next-generation antigen-presenting cell immune therapeutics for gliomas.
J Clin Invest. 2023 Feb 1;133(3):e163449. doi: 10.1172/JCI163449.
7
An armed oncolytic virus enhances the efficacy of tumor-infiltrating lymphocyte therapy by converting tumors to artificial antigen-presenting cells in situ.
Mol Ther. 2022 Dec 7;30(12):3658-3676. doi: 10.1016/j.ymthe.2022.06.010. Epub 2022 Jun 17.
8
A Comprehensive Investigation Regarding the Differentiation of the Procurable COVID-19 Vaccines.
AAPS PharmSciTech. 2022 Mar 21;23(4):95. doi: 10.1208/s12249-022-02247-3.
9
The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease.
Mol Ther. 2022 Jun 1;30(6):2130-2152. doi: 10.1016/j.ymthe.2022.02.002. Epub 2022 Feb 9.
10
Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia.
Best Pract Res Clin Haematol. 2021 Sep;34(3):101305. doi: 10.1016/j.beha.2021.101305. Epub 2021 Aug 27.
本文引用的文献
1
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy.
Nat Med. 2010 May;16(5):565-70, 1p following 570. doi: 10.1038/nm.2128. Epub 2010 Apr 18.
2
Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.
Biol Blood Marrow Transplant. 2010 Sep;16(9):1245-56. doi: 10.1016/j.bbmt.2010.03.014. Epub 2010 Mar 19.
3
Dynamic regulation of functionally distinct virus-specific T cells.
Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3669-74. doi: 10.1073/pnas.0915168107. Epub 2010 Feb 4.
4
Overview of a HLA-Ig based "Lego-like system" for T cell monitoring, modulation and expansion.
Immunol Res. 2010 Jul;47(1-3):248-56. doi: 10.1007/s12026-009-8156-z.
5
In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer.
Cancer Res. 2009 Dec 15;69(24):9376-84. doi: 10.1158/0008-5472.CAN-09-0400.
6
A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy.
Immunity. 2009 Nov 20;31(5):834-44. doi: 10.1016/j.immuni.2009.09.015. Epub 2009 Oct 29.
7
Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.
Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17469-74. doi: 10.1073/pnas.0907448106. Epub 2009 Sep 24.
8
Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.
Mol Ther. 2010 Feb;18(2):413-20. doi: 10.1038/mt.2009.210. Epub 2009 Sep 22.
9
Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures.
Nat Rev Cancer. 2009 Sep;9(9):675-81. doi: 10.1038/nrc2717.
10
A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy.
J Immunol. 2009 Aug 15;183(4):2837-50. doi: 10.4049/jimmunol.0804178. Epub 2009 Jul 27.
Zotero 插件